Articles citing this paper
Mass Spectrometry Investigation of Glycosylation Aberration via De-N-Glycopeptide Analysis
Vivekananda Shetty A B C and Ramila Philip AA Immunotope, Inc., 3805 Old Easton Road, Doylestown, PA 18902, USA.
B Current address: Progenics Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
C Corresponding author. Email: vivek@immunotope.com
![]() Dr Vivek Shetty received his Ph.D in mass spectrometry from the Indian Institute of Chemical Technology, India. He was also the recipient of the prestigious Humboldt Fellowship. Dr Shetty has published 42 research articles on mass spectrometry-based genomics and proteomics. As a Director at Immunotope, Inc., he led the analytical team which discovered novel glycoprotein biomarkers and MHC peptide antigens in cancer and infectious diseases. He is currently working as a scientist at Progenics Pharmaceuticals, Inc., in New York. Dr Shetty's research interests are in glycoprotein biomarker and MHC peptide antigen discovery, cysteine proteomics, and the characterization of antibodies and antibody drug conjugates. |
![]() Dr Ramila Philip is the scientific founder of Immunotope, Inc., and is currently the President and Chief Scientific Officer. She earned her Ph.D. in immunology in India and did post-doctoral training at the Institute of Immunology, Basel, Switzerland, and was a junior faculty member at the Cancer Research Institute, UCSF. She has held a number of senior level positions in pharmaceutical and biotechnology companies, and currently holds an adjunct professorship at Drexel University and a professorship at the Institute for Hepatitis and Virus Research. Dr Philip's research focus is in immunotherapy and clinical studies. She has over 75 peer-reviewed publications to her name. |
Australian Journal of Chemistry 66(7) 770-780 https://doi.org/10.1071/CH13159
Submitted: 9 April 2013 Accepted: 7 June 2013 Published: 10 July 2013